» Articles » PMID: 39598605

Enteric Delayed-Release Granules Loading Dendrobine Ameliorates Hyperlipidemia in Mice by Regulating Intestinal Flora Composition

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Nov 27
PMID 39598605
Authors
Affiliations
Soon will be listed here.
Abstract

: In this paper, we created enteric delayed-release granules that load Dendrobine (DNL) directly into the intestinal flora of hyperlipidemic mice, based on the relationship between intestinal flora and hyperlipidemia. : We then used pharmacodynamics and 16 Sr RNA high-throughput sequencing to examine the hypolipidemic effects and mechanism of these granules. Solvent evaporation was used to create the DNL, which was then characterized using FT-IR, XRD, SEM, and DSC. A high-fat diet was used to create the mouse model of hyperlipidemia in C57BL/6J mice. Dendrobine, various dosages of DNL, TMAO, and the combination of TMAO and DNL were subsequently gavaged on the mice. The makeup of the intestinal flora in the mouse colon was analyzed using 16S rRNA sequencing, and the effectiveness and mechanism of DNL in controlling the intestinal flora for the treatment of hyperlipidemia in mice were investigated. : The findings showed that DNL could effectively improve the dysbiosis brought on by hyperlipidemia by significantly lowering the mice's body weight and blood lipid level ( < 0.05), while also regulating the function of their intestinal flora, increasing the abundance of Actinobacteria ( < 0.05) and Thick-walled bacterium ( < 0.05), and decreasing the abundance of Desulfovibrio ( < 0.05) and Mycobacterium anisopliae ( < 0.05) in the intestinal flora of mice, inhibiting the growth of intestinal harmful microorganisms, providing space for the reproduction of beneficial bacteria, and thus maintaining the stability of the intestinal flora's structure.

Citing Articles

Elucidating the anticancer potential of dendrobine in renal cell carcinoma treatment.

Jia X, Chen Z, Chen X, Zhang H, Sun Z, Wang Z Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39774907 DOI: 10.1007/s00210-024-03774-5.

References
1.
Xu F, Yu Z, Liu Y, Du T, Yu L, Tian F . A High-Fat, High-Cholesterol Diet Promotes Intestinal Inflammation by Exacerbating Gut Microbiome Dysbiosis and Bile Acid Disorders in Cholecystectomy. Nutrients. 2023; 15(17). PMC: 10489946. DOI: 10.3390/nu15173829. View

2.
Wang S, Ren H, Zhong H, Zhao X, Li C, Ma J . Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut Microbes. 2021; 14(1):2003176. PMC: 8726654. DOI: 10.1080/19490976.2021.2003176. View

3.
Feng Y, Jia B, Feng Q, Zhang Y, Chen Y, Meng J . Dendrobine attenuates gestational diabetes mellitus in mice by inhibiting Th17 cells. Basic Clin Pharmacol Toxicol. 2020; 128(3):379-385. DOI: 10.1111/bcpt.13524. View

4.
Vourakis M, Mayer G, Rousseau G . The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis. Int J Mol Sci. 2021; 22(15). PMC: 8347163. DOI: 10.3390/ijms22158074. View

5.
Liu M, Shi W, Huang Y, Wu Y, Wu K . Intestinal flora: A new target for traditional Chinese medicine to improve lipid metabolism disorders. Front Pharmacol. 2023; 14:1134430. PMC: 10014879. DOI: 10.3389/fphar.2023.1134430. View